Abstract
Relevant pandemic-spread scenario simulations provide guiding principles for containment and mitigation policy developments. Here we devise a simple model to predict the effectiveness of different mitigation strategies. The model consists of a set of simple differential equations considering the population size, reported and unreported infections, reported and unreported recoveries and the number of Covid-19-inflicted deaths. For simplification, we assume that Covid-19 survivors are immune (e.g. mutations are not considered) and that the virus can only be passed on by persons with undetected infections. While the latter assumption is a simplification (it is neglected that e.g. hospital staff may be infected by detected patients with symptoms), it was introduced here to keep the model as simple as possible. Moreover, the current version of the model does not account for age-dependent differences in the death rates, but considers higher mortality rates due to temporary shortage of intensive care units. Some of the model parameters have been fitted to the reported cases outside of China1 from January 22 to March 12 of the 2020 Covid-19 pandemic. The other parameters were chosen in a plausible range to the best of our knowledge. We compared infection rates, the total number of people getting infected and the number of deaths in six different scenarios. Social distancing or increased testing can contain or drastically reduce the infections and the predicted number of deaths when compared to a situation without mitigation. We find that mass-testing alone and subsequent isolation of detected cases can be an effective mitigation strategy, alone and in combination with social distancing. However, unless one assumes that the virus can be globally defeated by reducing the number of infected persons to zero, testing must be upheld, albeit at reduced intensity, to prevent sub-sequent waves of infection. The model suggests that testing strategies can be equally effective as social distancing, though at much lower economical costs. We discuss how our mathematical model may help to devise an optimal mix of mitigation strategies against the Covid-19 pandemic. The website corona-lab.ch provides an interactive simulation tool based on the presented model.
Lay Summary The Covid-19 pandemic is a serious threat that can be mitigated by different strategies. Social isolation is currently practiced in most countries in Europe, at least until alternative mitigation strategies can be implemented or therapies and vaccines become available. We have formulated a simple mathematical model to estimate how well social isolation or improved identification of Covid-19 infected people can slow down virus spread and reduce the death toll.
Thereby, we found that improving Covid-19 detection is a highly efficient mitigation strategy. This could be achieved by ramping up testing and following up transmission contacts. These measures can complement and might eventually replace isolation strategies. Testing a random fraction of the susceptible population every day could stop spread of the pandemic. However, unless the virus can be defeated completely and globally, social distancing and/or improved Covid-19 detection must be maintained until therapies or vaccines become available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
HG acknowledges funding from the Swiss National Science Foundation (grant number 174060). Research in the Hardt lab is supported by the Swiss National Science foundation (310030_192567, NCCR Microbiomes, NRP72 407240-167121).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used for preparation of this manuscript is publicly available.